Shanghai RNACure Biopharma Co., Ltd.
PrivateLast Round
Series A
Extension
May 23, 2022
Company Overview
Shanghai RNACure Biopharma Co., Ltd. is a biotechnology company that develops mRNA-based vaccines and therapeutic platforms for infectious diseases, immuno-oncology, and rare diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shanghai RNACure Biopharma Co., Ltd. Comparables
Compare Shanghai RNACure Biopharma Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innovac Therapeutics | 86% | |
| RNAimmune | 84% | |
| WestGene Biopharma | 84% |
Shanghai RNACure Biopharma Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | May 23, 2022 | ||||
| Series A | Sep 27, 2021 | ||||
| Pre Seed | Mar 29, 2021 | ||||
| Angel | Jan 11, 2021 |
Shanghai RNACure Biopharma Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bencao Capital | Series A |
| Guoke Jiahe Capital | Pre Seed |
| Shine Asset | Series A |
| CoStone Capital | Series A Extension |
| LYZZ Capital | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 23, 2022
CoStone Capital and China State-Owned Capital Venture Investment Fund participated.
- Mar 29, 2021
Raised capital from Guoke Jiahe Capital and LYZZ Capital.
Shanghai RNACure Biopharma Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Shanghai RNACure Biopharma Co., Ltd.'s valuation, stock price, and market status.
Is Shanghai RNACure Biopharma Co., Ltd. a public or private company?
Shanghai RNACure Biopharma Co., Ltd. is a private company.
What is the current stock price of Shanghai RNACure Biopharma Co., Ltd.?
Shanghai RNACure Biopharma Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.
How much is Shanghai RNACure Biopharma Co., Ltd. worth (valuation)?
Valuation information for Shanghai RNACure Biopharma Co., Ltd. is not publicly available.
Can I buy Shanghai RNACure Biopharma Co., Ltd. stock?
Shanghai RNACure Biopharma Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Shanghai RNACure Biopharma Co., Ltd.'s last funding round?
Shanghai RNACure Biopharma Co., Ltd.'s most recent funding round was Series A Extension on May 23, 2022.
Who are the main investors in Shanghai RNACure Biopharma Co., Ltd.?
Key investors in Shanghai RNACure Biopharma Co., Ltd. include Bencao Capital, Guoke Jiahe Capital, Shine Asset, CoStone Capital, LYZZ Capital.
Will Shanghai RNACure Biopharma Co., Ltd. IPO soon?
No public IPO plans have been announced for Shanghai RNACure Biopharma Co., Ltd..
How can I track Shanghai RNACure Biopharma Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shanghai RNACure Biopharma Co., Ltd.'s secondary market activity and sign up for updates.